Literature DB >> 30784906

Lactobacillus rhamnosus GG strain mitigated the development of obstructive sleep apnea-induced hypertension in a high salt diet via regulating TMAO level and CD4+ T cell induced-type I inflammation.

Jing Liu1, Tianxiang Li2, Hui Wu1, Haoze Shi1, Jinmei Bai3, Wei Zhao3, Donghui Jiang4, Xiufeng Jiang5.   

Abstract

Obstructive sleep apnea (OSA) and high salt content in modern diet has been particularly implicated in systemic hypertension, leading to increased morbidity and mortality. Gut dysbiosis, associated with increased risk of systemic immunological imbalance, plays a causal role in the development of cardiovascular diseases. Here, we investigated the effect of Lactobacillus rhamnosus GG strain (LGG) on the development of hypertension induced by OSA and high salt diet. In this study, hypertension was modeled in rats by feeding a high salt diet (HSD) for 6 wk and exposuring to chronic intermittent hypoxia (CIH) during the sleep cycle. We found that OSA combined with HSD increased the severity of hypertension through increasing level of blood Trimethylamine-Oxide (TMAO), release of Th1-related cytokine (IFN-γ) and inhibition of anti-inflammatory cytokine (TGF-β1), and affected the gut microbiome in rats, particularly by depleting Lactobacillus. In addition, expression of PERK1/2, PAkt and PmTOR increased in the aorta from rats with a CIH exposure and HSD. Consequently, treatment of model rats with LGG prevented aggravation of hypertension by reducing blood TMAO levels, modulating Th1/Th2 cytokine imbalance and suppressing phosphorylation levels of ERK1/2, Akt and mTOR. In line with these findings, our results connect high salt diet to the gut-immune axis and highlight the gut microbiome as a potential therapeutic target to counteract the development of OSA-induced hypertension basing on a high salt diet.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Chronic intermittent hypoxia; High salt diet; Hypertension; Immune system; Microbiota

Mesh:

Substances:

Year:  2019        PMID: 30784906     DOI: 10.1016/j.biopha.2019.01.041

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  19 in total

1.  Obstructive Sleep Apnea and Systemic Hypertension: Gut Dysbiosis as the Mediator?

Authors:  Saif Mashaqi; David Gozal
Journal:  J Clin Sleep Med       Date:  2019-10-15       Impact factor: 4.062

2.  Diurnal Timing Dependent Alterations in Gut Microbial Composition Are Synchronously Linked to Salt-Sensitive Hypertension and Renal Damage.

Authors:  Saroj Chakraborty; Juthika Mandal; Xi Cheng; Sarah Galla; Anay Hindupur; Piu Saha; Beng San Yeoh; Blair Mell; Ji-Youn Yeo; Matam Vijay-Kumar; Tao Yang; Bina Joe
Journal:  Hypertension       Date:  2020-05-26       Impact factor: 10.190

3.  Rapamycin ameliorates chronic intermittent hypoxia and sleep deprivation-induced renal damage via the mammalian target of rapamycin (mTOR)/NOD-like receptor protein 3 (NLRP3) signaling pathway.

Authors:  Wei Liu; Dong Zhao; Xiaofeng Wu; Fang Yue; Haizhen Yang; Ke Hu
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

Review 4.  Gut Microbiota-Derived Short-Chain Fatty Acids Facilitate Microbiota:Host Cross talk and Modulate Obesity and Hypertension.

Authors:  Haley B Overby; Jane F Ferguson
Journal:  Curr Hypertens Rep       Date:  2021-02-03       Impact factor: 5.369

Review 5.  Sequence meets function-microbiota and cardiovascular disease.

Authors:  Myungsuk Kim; Md Nazmul Huda; Brian J Bennett
Journal:  Cardiovasc Res       Date:  2022-01-29       Impact factor: 10.787

Review 6.  The gut microbiome as a target for adjuvant therapy in obstructive sleep apnea.

Authors:  Mohammad Badran; Saif Mashaqi; David Gozal
Journal:  Expert Opin Ther Targets       Date:  2020-12-04       Impact factor: 6.797

Review 7.  Implication of Gut Microbiota in Cardiovascular Diseases.

Authors:  Wenyi Zhou; Yiyu Cheng; Ping Zhu; M I Nasser; Xueyan Zhang; Mingyi Zhao
Journal:  Oxid Med Cell Longev       Date:  2020-09-26       Impact factor: 6.543

8.  Effects of Probiotics on Patients with Hypertension: a Systematic Review and Meta-Analysis.

Authors:  Cheng Chi; Cheng Li; Dongjun Wu; Nicholas Buys; Wenjun Wang; Huimin Fan; Jing Sun
Journal:  Curr Hypertens Rep       Date:  2020-03-21       Impact factor: 5.369

9.  Prebiotic administration modulates gut microbiota and faecal short-chain fatty acid concentrations but does not prevent chronic intermittent hypoxia-induced apnoea and hypertension in adult rats.

Authors:  Karen M O'Connor; Eric F Lucking; Thomaz F S Bastiaanssen; Veronica L Peterson; Fiona Crispie; Paul D Cotter; Gerard Clarke; John F Cryan; Ken D O'Halloran
Journal:  EBioMedicine       Date:  2020-08-30       Impact factor: 8.143

Review 10.  Modulation of the PI3K/Akt/mTOR signaling pathway by probiotics as a fruitful target for orchestrating the immune response.

Authors:  Amir Hossein Mohseni; Vincenzo Casolaro; Luis G Bermúdez-Humarán; Hossein Keyvani; Sedigheh Taghinezhad-S
Journal:  Gut Microbes       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.